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ABSTRACT
The tumor suppressor p53 plays a pivotal role in numerous cellular responses as 
it regulates cell proliferation, metabolism, cellular growth, and autophagy. In order 
to identify novel p53 target genes, we utilized an unbiased microarray approach 
and identified Rap2B as a robust candidate, which belongs to the Ras-related GTP-
binding protein superfamily and exhibits increased expression in various human 
cancers. We demonstrated that p53 increases the intracellular IP3 and Ca2+ levels 
and decreases the LC3 protein levels through its target gene Rap2B, suggesting that 
p53 can inhibit the autophagic response triggered by starvation via upregulation of 
the Rap2B-PLCε-IP3-Ca2+ pathway. As a confirmed target gene of p53, we believe that 
further investigating potential functions of Rap2B in autophagy and tumorigenesis 
will provide a novel strategy for cancer therapy.
INTRODUCTION
p53 is regarded as a central stress sensor and a DNA 
sequence-specific transcription factor [1]. p53 is stabilized 
in response to various stresses including oxidative stress, 
genotoxic damage, and oncogenic growth signals before 
regulating numerous downstream target genes that exert 
various cellular responses dependent on both the type of 
stress and cellular context [2-4]. Previous studies have 
established the vital role of p53 in regulation of cell cycle 
arrest, senescence, DNA repair, apoptosis, and autophagy 
[5-7]. However, the exact mechanisms as to how p53 
exerts so many diverse effects remain unclear. The current 
understanding of p53-mediated autophagic regulation is 
particularly complex and ambiguous. Therefore, even 
though a significant list of p53 target genes has been 
detailed previously [8], it is still of great importance to 
identify and study novel p53 downstream targets in order 
to gain a more complete understanding of the p53 stress 
response pathway. Here, we confirm Rap2B as a target 
gene of p53 that is involved in the regulation of p53 
induced autophagy.
Rap2B, a Ras family protein, was initially 
discovered from a screened platelet cDNA library in 
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the early 1990s [9]. We found that Rap2B was highly 
expressed in multiple human cancers. Previous studies 
have determined that in response to activation of the EGF 
receptor Rap2B promotes the activation of phospholipase 
C-ε (PLCε), a pivotal enzyme localized to the plasma 
membrane, eliciting a range of biological functions [10-
13]. In previous studies, we showed that Rap2B could 
be induced by nocodazole treatment to regulate the 
cytoskeleton in a p53-dependent fashion. Additionally, we 
demonstrated that Rap2B promoted migration and invasion 
of human breast cancer and suprarenal epithelioma [7, 14].
Significantly, Mestre et al. have reported that Rap2b along 
with cAMP, EPAC, and calpain activation negatively 
regulate Hla-induced autophagy, indicating that Rap2B is 
involved in the autophagic pathway [15].
Cell stresses, such as nutrient deprivation, oxidative 
stress, and the accumulation of damaged organelles, 
activate autophagy to mediate cellular self-catabolism 
and recycling through lysosomes, thus maintaining 
homeostasis as well as survival [16, 17]. Genetic analysis 
has resulted in the discovery of several autophagy-
related genes (ATGs), which play key roles in facilitating 
autophagosome formation and the regulation of autophagy 
[16, 18]. The mechanisms by which autophagy is regulated 
are complicated with inputs from various signaling 
cascades including p53 and some of its transcriptional 
target genes [2, 7, 19]. Nuclear p53 enhances autophagy 
primarily through the activation of AMP-kinase (AMPK) 
resulting in the downregulation of mammalian target 
of rapamycin (mTOR), which functions as an inhibitor 
of autophagy. Conversely, cytoplasmic p53 can inhibit 
autophagy [20]. In previous publications [21-24], it was 
revealed that reducing intracellular inositol triphosphate 
(IP3) levels or genetic knockdown of the IP3 receptor 
induces autophagy independent of mTOR regulation via 
Bcl-2-mediated release of Beclin 1, thus linking IP3 with 
the regulation of autophagy. Furthermore, Mestre et al. 
suggest that Rap2B links both the classical autophagic 
pathway induced by starvation and the ‘‘non-canonical’’ 
autophagy pathway triggered by toxins [15]. 
Based on the research detailed above, we expect 
that p53, through its target gene Rap2B, participates in the 
regulation of the autophagic response. In the present study, 
we demonstrate that Rap2B is an effector of p53 stress 
response by upregulating the PLCε-IP3-Ca2+ pathway and 
inhibiting autophagy triggered by starvation.
RESULTS
Rap2B is a p53 transcriptional target
A previous study by our laboratory has demonstrated 
that the expression of p53 can be controlled by 
manipulating Mdm2 expression through the generation of 
Figure 1: Rap2B is a p53 transcriptional target. A. Mouse embryonic fibroblasts harboring a single p53ER fusion allele and a p53 
null allele (p53ER/- MEF) cell lines with the indicated Mdm2 genotypes including Mdm2 +/+, Mdm2 -/-, or C462A (m/m) Mdm2 were 
treated for 24 h with 4-OHT. Cells were harvested and analyzed by western blot. B. Corresponding microarray Log2 expression values of 
p53ER/- MEF cell lines following 24 h treatment with 4-OHT. C. p53ER/- MEF cell lines with the indicated Mdm2 genotypes were treated 
for 24 h with 4-OHT. Cells were harvested and analyzed by real-time PCR for expression of Rap2B and p21 mRNA. 
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mice bearing Mdm2 WT (+/+), null (-/-), or RING finger 
C462A point mutation (m/m) alleles [25]. In addition, 
the switchable p53ERTAM (p53ER hereafter) allele was 
introduced into mice to facilitate modulation of p53 
transactivation function in which the endogenous Trp53 
(p53) gene is replaced by one encoding p53ER. p53ER 
expresses a full-length p53 protein fused C-terminally 
with the hormone binding domain of a modified estrogen 
receptor and is transcriptionally regulated in the same 
manner as WT p53. Therefore, p53ER activity can be 
turned ‘‘on’’ or ‘‘off’’ by administration or withdrawal of 
4-hydroxytamoxifen (4-OHT) in this inducible system 
[26].
We previously observed the transactivation ability 
of p53ER to be low, medium, and high across Mdm2 WT, 
null, and C462A (m/m) MEF cells respectively, which 
provides a unique system to study p53 transactivation 
potential at close to physiological levels. We then 
performed a microarray experiment screening for novel 
p53 candidate target genes by using these p53ER MEF 
cell lines [25]. We identified a large number of the genes 
identified previously in a ChIP-chip array [27]. Rationally, 
candidate genes should meet the arbitrary low-medium-
high Log
2
 expression threshold. One such candidate gene 
was Rap2B, a member of the Ras family; moreover, we 
found that most carcinoma cells expressed higher levels of 
Rap2B than in the non-cancerous immortalized BJ or WI-
38 cell lines (Supplementary Figure 1). Although Rap2B 
induction was low in the Mdm2 WT MEF cells after p53 
activation, the Mdm2 null and C462A (m/m) MEF cells 
exhibited comparatively moderate-to-high expression 
levels of Rap2B (Figure 1A). Rap2B protein levels 
induced by 4-OHT mirrored the Log2 expression values 
indicated by the microarray (Figure 1B), thereby providing 
a strong correlation between transcript and protein levels. 
To confirm the result from the microarray, we performed 
real-time PCR to monitor the induction of Rap2B mRNA 
in the above MEF cells treated with or without 4-OHT. 
Our results showed that the induction of Rap2B mRNA 
was p53-dependent with the canonical p53 target gene 
Cdkn1a (p21) as a positive control (Figure 1C).
Figure 2: Rap2B gene locus contains p53-binding sites. A. Luciferase reporter assay to measure the induction of Rap2B promoter 
by p53. B. Chromatin immunoprecipitation (ChIP) assay to measure the binding of p53 in the promoter region of the Rap2B gene in 
p53ER/- MEF cells treated with 4-OHT.
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Rap2B gene locus contains p53-binding sites
To determine whether Rap2B is a direct target of 
p53, we carried out a heterologous promoter-reporter 
assay using a luciferase vector pGl3-Rap2B-p(1-6) (p1-6 
corresponding to -3,000~+3,000 bp to the transcriptional 
start site), which was prepared by cloning the nucleotide 
sequence around the Rap2B promoter. Figure 2A shows 
a p53 dependent increase in luciferase activity from 
pGl3-Rap2B-p2 when compared to the empty vector 
alone. We then searched for a consensus p53-binding 
sequence within the genomic locus containing the human 
Rap2B gene. A single potential binding site (designated 
p2, corresponding to -2,000 ~-1,000 bp to the TSS) was 
identified consisting of two copies of the 10-bp consensus 
p53-binding motif and the sequence is well conserved 
between mouse and human (Supplementary Figure 2). 
We then utilized an in vivo chromatin 
immunoprecipitation assay (ChIP) to confirm the direct 
binding of p53 on the Rap2b gene. ChIP assays using 
anti-p53 antibodies revealed that a DNA fragment 
containing the p2 sequence was reproducibly present 
in the immunoprecipitated complex containing the p53 
protein, indicating that p53 binds to the p2 site in vivo. As 
Figure 3: ActD and UV induce Rap2B in WT, but not p53-null, MEF or HCT116 cells. A., B. WT and p53-null HCT116 cells 
were treated with 5 nM ActD or 40J UV for various times. Cells were harvested and analyzed by western blot. C., D. WT and p53-null MEF 
cells were treated with 5 nM ActD or 40J UV for various times followed by western blot. 
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a positive control for the ChIP assay, we found that p53 
strongly binds to the p21 promoter (Figure 2B). Thus, our 
findings provide clear evidence that there is a functional 
p53 response element in the promoter region of the Rap2B 
gene.
ActD and UV induce Rap2B in WT, but not p53-
null, MEF or HCT116 cells
Since p53 is established as a stress sensor that is 
activated by diverse stimuli [4], we investigated whether 
Rap2B could be induced in response to diverse stresses 
in a p53 dependent manner. Actinomycin D (ActD) has 
been used as a chemotherapeutic drug in the treatment of 
a variety of human cancers [28]. At high concentrations 
(e.g. >30 nM) of ActD causes DNA damage and inhibits 
transcription from all three classes of RNA polymerases, 
whereas at low concentrations (e.g. <10 nM) ActD does 
not cause DNA damage but selectively inhibits RNA pol 
I-dependent transcription to directly shut down ribosomal 
biogenesis [29, 30]. Therefore, in addition to DNA 
damage in response to UV treatment, we also use non-
genotoxic doses of ActD (5 nM) to activate p53. MEF 
(p53+/+, p53−/−) and HCT116 (p53+/+, p53−/−) cells were 
treated with/without ActD or UV followed by western 
blot analysis to evaluate Rap2B and p53 protein levels. 
As shown in Figure 3, both ActD and UV promoted 
the stabilization and activation of p53 in both MEF 
and HCT116 p53+/+ cells as expected. Accordingly, the 
protein levels of Rap2B increased significantly in p53+/+ 
cells treated with ActD or UV, but not in p53-/- cells. Our 
results indicate that Rap2B is a p53 inducible target and 
can be activated by ribosomal biogenesis stress and DNA 
damage. However, it is important to note that the protein 
levels of Rap2B increased slightly at 24 h in p53-/- cells 
treated with ActD, which suggests that a portion of the 
Rap2B protein expression in response to ribosomal stress 
could be p53 independent.
p53 increases the intracellular IP3 level through 
Rap2B
Previous studies [11, 31] have established that 
Rap2B induces PLCε stimulation. Stimulation of 
PLCε catalyzes the breakdown of phosphatidylinositol 
4,5-bisphosphate (PIP2) into the second messengers 
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate 
(IP3), which activate protein kinase C and Ca2+ 
release from intracellular stores, leading to a cascade 
of intracellular events including regulation of cell 
growth, cell differentiation, and gene expression [32, 
33]. Therefore, we performed ELISA to determine the 
intracellular IP3 levels in U2OS and HCT116 cells under 
various levels of Rap2B and p53. The knockdown or 
overexpression of Rap2B and p53 was determined by 
western blot as shown in Figure 4, left panels. Our results 
revealed that intracellular IP3 levels were increased after 
exogenous expression of p53 or Rap2B in U2OS cells 
(Figure 4A, right panels), whereas knockdown of either 
p53 or Rap2B decreased intracellular IP3 levels (Figure 
4B, right panels). This direct relationship between Rap2B 
expression and IP3 levels was also observed in HCT116 
cells (Figure 4C, 4D, right panel). Additionally, we 
detected decreased levels of IP3 in HCT116 p53-/- cells 
compared with p53+/+ cells (Figure 4C, 4D, right panel). 
Furthermore, we utilized ActD or UV treatment to confirm 
whether p53 increases the intracellular IP3 level through 
Rap2B. U2OS cells were transfected with siRNA against 
Rap2B and p53, and then treated with/without ActD or 
UV. The protein levels of Rap2B and p53 were detected 
by western blot analysis. In response to both ActD and 
UV driven p53 activation, the expression level of Rap2B 
was increased, while knocking down p53 decreased the 
observed levels of Rap2B significantly (Figure 4E, 4F, left 
panels). Accordingly, the level of IP3 was also distinctly 
increased when treated with ActD or UV and abrogated 
by knocking down either Rap2B or p53 in both cell lines 
(Figure 4E, 4F, right panels). Similar results were also 
observed in HCT116 cells (Supplementary Figure 3A, 3B). 
These results indicate that p53 increases the intracellular 
IP3 level through a Rap2B-dependent mechanism. 
p53 increases the intracellular Ca2+ level through 
Rap2B
IP3 interacts with a specific receptor located on the 
surface of the endoplasmic reticulum, resulting in a rapid 
rise in intracellular Ca2+ concentrations, which plays a 
crucial role in numerous cellular responses such as cell 
migration, apoptosis and autophagy [34, 35]. In order 
to determine whether the p53-Rap2B pathway regulates 
intracellular Ca2+ levels, we performed flow cytometry in 
transfected U2OS and HCT116 cells. As shown in Figure 
5A, overexpression of Rap2B or p53 was sufficient to 
increase the intracellular Ca2+ level in U2OS cells. In 
contrast, decreased levels of Ca2+ were detected after 
knocking down Rap2B or p53 (Figure 5B). Moreover, 
we observed an increase in Ca2+ levels in HCT116 cells 
transfected with Rap2B plasmid and the expected decrease 
in Ca2+ levels after knockdown of Rap2B. Predictably, 
the Ca2+ levels of p53-/- cells were lower than that of 
p53+/+ in HCT116 cells (Figure 5C and 5D). In Figure 
4/5D, IP3/Ca2+ was also decreased in response to Rap2B 
knockdown even in HCT116 p53-/- cells, which suggest 
that Rap2B could also mediate IP3 induction independent 
of p53. Additionally, both cell lines treated with ActD or 
UV displayed the expected increased levels of Ca2+, but 
these effects were blocked by targeting Rap2B or p53 
with specific siRNAs (Figure 5E, F and Supplementary 
Figure 4A, 4B). Taken together, our data show that Rap2B 
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Figure 4: p53 can increase the intracellular IP3 level through Rap2B in U2OS and HCT116 cells. A., C. U2OS cells or 
HCT116 (p53+/+, p53-/-) cells were transfected with myc tagged Rap2B, p53 and control plasmids. The protein levels of Rap2B and p53 
and the intracellular IP3 levels were measured by western blot analysis and an IP3 ELISA Kit, respectively. B., D. U2OS cells or HCT116 
(p53+/+, p53-/-) cells were transfected with siRNA against Rap2B and p53, the protein levels of Rap2B and p53 and the intracelluar IP3 
levels were measured by western blot analysis and an IP3 ELISA Kit, respectively. E., F. U2OS cells were transfected with siRNA against 
Rap2B and p53, cells were then either treated or untreated with 5 nM ActD or 40J UV for 4 h, the protein levels of Rap2B and p53 and the 
intracelluar IP3 levels were measured by western blot analysis and an IP3 ELISA Kit. All experiments were carried out in triplicate. Data 
are presented as mean ± SD (n = 3). *P < 0.05, **P< 0.01 in comparison with respective control group. 
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is a central participant in the regulation of p53-mediated 
increases of intracellular Ca2+.
p53 decreases the LC3 protein levels through 
Rap2B 
The data shown above indicate that p53 increases the 
intracellular IP3 and Ca2+ levels through its transcriptional 
target Rap2B. Mestre et al. [15] demonstrated that Rap2B 
was involved in the regulation of autophagy, and further 
proposed a model by which cAMP inhibits S. aureus-
induced autophagy through the participation of the Epac/
Rap2b/PLCε pathway and calpain activation. Specifically, 
when activated by cAMP/EPAC, Rap2B activates PLCε 
and induces an increase in IP3, which leads to Ca2+ release 
from the endoplasmic reticulum and then activates the 
calpain cysteine-proteases. These calpains are able to 
cleave Atg5 inhibiting the autophagic pathway. Therefore, 
we wanted to determine whether the p53-Rap2B pathway 
Figure 5: p53 can increase the intracellular Ca2+ level through Rap2B in U2OS and HCT116 cells. A., C. After U2OS cells 
or HCT116 (p53+/+, p53-/-) cells were transfected with Rap2B plasmids, p53 plasmids and control plasmids, the intracellular Ca2+ levels 
were measured by flow cytometry. B., D. After U2OS or HCT116 (p53+/+, p53-/-) cells were transfected with Rap2B siRNA, p53 siRNA and 
control siRNA, the intracellular Ca2+ levels were measured by flow cytometry. E., F. After U2OS cells were transfected, cells were either 
treated or untreated with 5 nM ActD or 40J UV for 4 h, the intracellular Ca2+ levels were measured by flow cytometry. All experiments 
were carried out in triplicate. Data are presented as mean ± SD (n = 3). *P < 0.05, **P < 0.01in comparison with respective control group. 
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Figure 6: p53 can decrease the LC3 protein level through Rap2B, and BAPTA-AM can disrupt the inhibition. A. After 
U2OS cells were transfected with Rap2B plasmids and control plasmids, cells were either treated with EBSS for starvation or untreated. 
Then, starved cells were incubated in the presence or absence of BAPTA-AM (30μM) for 30 min. The protein levels of Rap2B, LC3, and 
Actin were measured by Western blot in Rap2B overexpression and control group. B. After U2OS cells were transfected with Rap2B siRNA 
and control siRNA, cells were either treated with EBSS for starvation or untreated. Then, starved cells were incubated in the presence 
or absence of BAPTA-AM (30μM) for 30 min. The protein levels of Rap2B, LC3, and Actin were measured by Western blot in Rap2B 
overexpression and control group. C., D. After transfection and starvation, HCT116 cells were incubated in the presence or absence of 
BAPTA-AM (30μM) for 30 min, the protein levels of Rap2B, LC3, and Actin were measured by Western blot. All experiments were carried 
out in triplicate. Data are presented as mean ± SD (n = 3). **P< 0.01 in comparison with respective control group. 
Oncotarget64665www.impactjournals.com/oncotarget
participates in the regulation of autophagy induced by 
starvation in U2OS and HCT116 cells by tracking the 
conversion of LC3-I to LC3-II. 
Both cell lines were transfected with either Rap2B 
plasmid or Rap2B siRNA before being subjected to 
starvation conditions with Earle’s balanced salts solution 
(EBSS), which contains no nutrients except for glucose, 
or incubated in complete medium for two hours. Next, 
we carried out western blot analysis to determine the 
expression of lipidated LC3 (LC3-II), an autophagic 
marker. In U2OS cells with pcDNA3 or control siRNA 
transfection, EBSS treatment increased the conversion 
of endogenous LC3-I to LC3-II. However, the EBSS-
induced autophagic effect was substantially minimized 
by Rap2B overexpression, while knocking down Rap2B 
also dramatically increased LC3-I to LC3-II conversion 
(Figure 6A, 6B). Similar results were obtained in HCT116 
cells, and we also found an increased level of LC3-II in 
HCT116 p53−/− cells compared with HCT116 p53+/+ cells, 
indicating that deletion of p53 facilitated the activation of 
autophagy (Figure 6C, 6D). 
To further verify that Ca2+ participates in p53-
mediated autophagy inhibition through Rap2B, we 
assessed the effect of BAPTA-AM, a Ca2+ chelator, on the 
autophagic response induced by starvation. We incubated 
the transfected cells in the presence or absence of BAPTA-
AM (30μM) for 30 min before exposing the cells to EBSS. 
Our results indicate that while EBSS alone was able to 
induce autophagy that can be downregulated by p53 and 
Rap2B, these effects could be abolished by BAPTA-AM, 
further confirming the important role Ca2+ plays in the 
autophagic pathway (Figure 6). Collectively, these results 
indicate that p53 negatively regulates this autophagic 
response induced by starvation through Rap2B via Ca2+ 
signaling.
DISCUSSION
In response to multiple cellular stresses, the p53 
pathway is activated to achieve various functions through 
transactivation of numerous target genes [2]. However, 
the particular molecular mechanisms facilitating these 
versatile functions are still not clearly defined. Although 
p53 target genes have been well documented in recent 
years, further study of both p53 and novel target genes is 
still necessary. By studying p53 transcription target gene 
microarray data in this study, we have confirmed Rap2B 
as a novel p53 target (Figures 1-3). Furthermore, we show 
an important role for Rap2B in autophagy regulation. 
Specifically, Rap2B is able to upregulate the PLCε-IP3-
Ca2+ pathway and inhibit autophagy induced by starvation. 
Rap2B is a Ras family protein and is upregulated in many 
tumors, which could be a new therapeutic target for cancer.
Figure 7: A schematic diagram illustrating the proposed p53-induced Rap2B upregulates PLCε-IP3-Ca2+ pathway 
and inhibits autophagy. p53-induced Rap2B can increase the intracellular IP3 and calcium level. The elevated calcium subsequently 
activates calpains, which are able to cleave Atg5, inhibiting autophagy by decreasing the levels of Atg12-Atg5 conjugate. The calcium 
chelator BAPTA-AM could block this effect.
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Besides the canonical function of p53 as a tumor 
suppressor, an increasing number of new roles for p53 
have recently been established including the ability to 
regulate autophagy [2, 19]. During the past few years, it 
has been reported that p53 plays a complex role in the 
regulation of autophagy that depends on its subcellular 
localization. Nuclear p53 predominantly induces 
autophagy by transcriptional regulation of several pro-
autophagic factors that activate AMPK, a positive 
regulator of autophagy, while simultaneously down-
regulating the negative regulator of autophagy, mTOR [36, 
37]. However, cytoplasmic p53 largely inhibits autophagy. 
p53-induced glycolysis and apoptosis regulator (TIGAR) 
[38] suppresses autophagy by inhibiting ROS in response 
to metabolic stress or nutrient deprivation [2]. These data 
indicate that many target genes of p53 are involved in the 
regulation of autophagy. 
In this study, we confirmed Rap2B as a target gene 
of p53 and demonstrated that p53-induced Rap2B could 
negatively regulate autophagy triggered by starvation. 
Our data also suggest that p53-Rap2B increases the 
levels of intracellular IP3 and Ca2+ levels (Figure 4, 5). 
Consistent with our results, Mestre et al. have shown that 
the direct activation of Rap2B by cAMP was sufficient to 
inhibit autophagy induced by α-Hemolysin independent 
of the mTOR pathway, but dependent on the autophagic 
protein Atg5 [15]. Additionally, Rubinsztein and 
coworkers [39] demonstrated the importance of EPAC 
and its effector Rap2B in the regulation of autophagy. 
This study elucidated an mTOR-independent pathway 
regulating autophagy in which the direct activation of 
EPAC/Rap2B by cAMP activates PLCε to upregulate 
IP3 levels, which induces the release of Ca2+ from the 
endoplasmic reticulum. Multiple report shave shown 
that Rap2B stimulates PLCε and induces Ca2+ increase 
[31, 40, 41], which activates the calcium-dependent 
cysteine-protease calpains [42]. The activated calpains 
in turn are able to cleave Atg5 inhibiting the autophagic 
pathway. We speculate that the PLCε-IP3-Ca2+ pathway 
might be closely associated with p53 dependent inhibition 
of autophagy via Rap2B which is connected to the key 
autophagic protein Atg5, although the precise mechanism 
remains to be elucidated. 
To our knowledge, this study is the first to 
demonstrate that p53-Rap2B signaling pathway plays 
an effectively inhibitory effect on the starvation-induced 
autophagic response by upregulating PLCε-IP3-Ca2+ 
pathway. In support of this finding, a previous report has 
shown that reintroduction of wild-type p53 to HCT116 
p53−/− cells decreases baseline levels of autophagy [43]. 
Consistently, in our experiments, elevated levels of LC3-
II were observed in HCT116 p53−/− cells relative to p53+/+ 
cells, indicating that p53 can be an efficient inhibitor 
of autophagy. Meanwhile, we also observed that the 
inhibition of Ca2+ signaling by the Ca2+ chelating agent 
BAPTA-AM abolished the inhibitory effect of p53-Rap2B 
signaling on autophagy induced by starvation, which is 
similar to previous findings. Thus, it is likely that the 
intracellular Ca2+ levels are involved in the regulation of 
autophagy mediated by p53-Rap2B pathway. 
In summary, our results showed that Rap2B is a 
direct p53 target gene, through which p53 upregulates the 
PLCε-IP3-Ca2+ pathway to inhibit autophagy. Moreover, 
we speculate that the influence of p53-Rap2B signal on 
autophagy is connected to the key autophagic protein 
Atg5, rather than via the classical autophagy machinery 
based on the AMPK-dependent inhibition of mTOR, as 
shown in Figure 7. Given the established role of p53 in 
autophagy regulation and tumor suppression, as well 
as the validation of Rap2B as a p53 target gene, any 
potential interplay between p53, Rap2B, autophagy and 
tumor metabolism deserves further investigation. Further 
experiments are underway to explore the effect of p53-
mediated inhibition of autophagy through Rap2B on 
tumorigenesis, cancer cell proliferation, and migration 
by regulating the PLCε-IP3-Ca2+ signaling pathway using 
an in vivo tumor mouse model. Building on this study 
and other key findings we expect to develop potentially 
revolutionary new strategies for cancer therapy.
MATERIALS AND METHODS
Cell culture and transfection
U2OS, HCT116 and mouse embryo fibroblasts 
(MEF) cell lines were maintained in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine 
serum, L-glutamine, 100μg/ml penicillin, and 100μg/
ml streptomycin at 5% CO
2
 in a humidified chamber. 
Nonspecific control siRNA, p53 or Rap2B siRNA 
(Invitrogen, Shanghai, China) was transfected into U2OS 
and HCT116 cells at 60% confluence by siLentFect 
Lipid Reagent (Bio-Rad, Hercules, CA) according to the 
manufacturer’s protocol. The pcDNA3-Myc3-control, 
pcDNA3-p53 and pcDNA3-Myc3-Rap2B plasmids were 
constructed previously in our lab. Cells were grown to 
90% confluence before being transiently transfected with 
Rap2B plasmids using Lipofectamine 2000 (Invitrogen, 
Shanghai, China) according to the manufacturer’s 
protocol.
Microarray analysis
Total RNA was isolated from MEFs treated with 
4-hydroxytamoxifen (4-OHT) for 12 and 24 h using an 
RNeasy kit (Qiagen). One microgram of total RNA was 
amplified and labeled using the low RNA input linear 
amplification kit (Agilent Technologies, Wilmington, 
DE), and hybridization was performed on Agilent 4×44 
K mouse whole genome DNA microarrays. Arrays were 
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washed and scanned using an Agilent scanner (Agilent 
Technologies). Genes that were significantly up or down-
regulated were identified using significance analysis of 
microarrays. 
Chromatin immunoprecipitation (ChIP) assay
The ChIP assays were performed by using the ChIP 
Assay Kit (Upstate, Lake Placid, NY) with antibodies 
against mouse p53 (Santa Cruz, M19, Dallas, TX). The 
cells (2×106) were cross-linked with a 1% formaldehyde 
solution for 15 min at 37º. The cells were then lysed in 200 
ml of SDS lysis buffer and were sonicated to generate 300-
800 bp DNA fragments. After centrifugation, the cleared 
supernatant was diluted 10-fold with ChIP dilution buffer 
and incubated with the appropriate antibody (5 μg) at 4º 
for 16 h. One-fiftieth of the volume of the total extract was 
used for PCR amplification as the input control. Immune 
complexes were precipitated, washed and eluted, and 
DNA-protein crosslinks were reversed by heating at 65º 
for 4 h. The DNA fragments were purified and dissolved 
in 40 μl of TE. Recovered DNA was submitted for PCR 
amplification. The primer sequences for Rap2B are Rap2B 
-Ch015’-CCGAGACCAATGAGTGCAGAG-3’ and 
Rap2B-Ch025’-CATGCTCAGTCGC
AGAGCAG-3’. For p21, the primer sequences are 
p21-Ch015’-GTGGCTCTGATTGGCTT
TCT-3’ and p21-Ch025’-
CTGAAAACAGGCAGCCCAAGG-3’.The PCR products 
generated based on the ChIP template were separated 
on 1% agarose gel and visualized under UV light after 
staining with ethidium bromide. 
Luciferase reporter assay
Luciferase reporter assay was performed using 
Dual-Luciferase Reporter Assay System (Promega, 
Madison, WI) according to the manufacturer’s 
instructions. Rap2B-p(1-6) promoter were subcloned into 
pGl3 luciferase vector (for the primer’s sequences see 
Supplementary Table 1). The resulting constructs were 
confirmed by sequencing. In brief, 100 ng pGl3-Rap2B 
(promoter) was co-transfected into H1299 cells with 
or without 10 ng pcDNA3.1-p53. Fold induction was 
calculated to evaluate the relative activities of the Rap2B 
promoter and expressed as the signal with p53 over the 
signal without p53. The experiments were repeated at least 
three times to calculate the average of fold induction.
Measurement of intracellular IP3
The intracellular IP3 concentration in U2OS and 
HCT116 cells was measured by using Human inositol 
1, 4, 5,-trisphosphate (IP3) ELISA Kit (Cusabio, China). 
After transfection, the cells were diluted to 1×100/ml with 
PBS, and then lysed to release intracellular components 
by repeated freezing and thawing. The supernatant was 
carefully collected after centrifuging for 20 min at 2,000-
3,000 rpm. According to the manufacturer’s protocol, 
absorbance O.D. of each well was determined by using a 
microplate reader set to 450 nm. By using the professional 
soft “Curve Expert 1.3” to make a standard curve, the IP3 
concentrations were calculated.
Measurement of intracellular calcium
The intracellular calcium concentration in U2OS 
and HCT116 cells was examined by the Ca2+-sensitive 
fluorescent dye Fulo 3-AM (Dojindo Laboratories, 
Japan). After transfection and specific treatments, cells 
were washed with HBSS three times and incubated in 
1000μl HBSS containing 5μl Fluo 3-AM for 1 h at 37ºC 
in the dark. Subsequently, cells were washed with HBSS 
for three times and analyzed by using a FACSCanto flow 
cytometer (BD Biosciences, San Jose, CA).
Western blot
After specific treatments, cells were incubated in 
lysis buffer (Roche Molecular Biochemicals, Mannheim, 
Germany) for 20 min on ice. After insoluble debris was 
pelleted by centrifugation at 14,000g for 15 min at 4º, the 
supernatants were collected and determined for protein 
content using the bicinchoninic acid (BCA) kit (Pierce, 
USA) according to the manufacturer’s instructions. 
Proteins (80μg) were resolved under denaturing conditions 
by SDS-PAGE (10%) and transferred onto nitrocellulose 
membranes. After blocking for 2 h in phosphate-buffered 
saline with 0.1% Tween-20 (PBST) and 3% bovine serum 
albumin (BSA), membranes were incubated overnight 
at 4º with the appropriate primary antibody in PBST 
containing 3% BSA. Membranes were then washed and 
incubated with secondary antibodies conjugated with 
IRDye 680 or IRDye 800 (Sigma, 1:10 000) in PBST for 
2 h. The corresponding bands were imaged with Odyssey 
infrared imaging system (Li-COR Lincoln, NE). 
Antibodies
The following antibodies were purchased 
commercially: mouse anti-Mdm2 2A10 (University of 
North Carolina Tissue Culture and Molecular Biology 
Support Facility), mouse anti-actin (Neomarkers), mouse 
anti-p53 DO.1 (Neomarkers), rabbit anti-Rap2B (Abcam), 
and goat anti-p21 (C-19) (Santa Cruz Biotechnology), 
rabbit anti-LC3 (Novus Biologicals).
Oncotarget64668www.impactjournals.com/oncotarget
Statistical analysis
Data are expressed as the means ± SD. The 
Dunnett’s t test was used to assess differences within 
treatment groups. All experiments were carried out at least 
three times. Differences were considered significant when 
P < 0.05.
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